NASDAQ · Biotechnology

WHWK (WHWK) Stock

$4.07 -1.69% NASDAQ: WHWK Healthcare

Valuation

MetricValue
Price$4.07
Market Cap$201.27M
P/E Ratio-12.79
P/B Ratio1.53
P/S Ratio29.81
EPS (TTM)$-0.33
52-Week High$5.50
52-Week Low$1.57
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-15.44%
ROA-13.91%
ROCE-83.82%
Gross Margin-1642.86%
Operating Margin-1628.57%
Net Margin-300.00%
Debt/Equity0.00
Current Ratio9.93

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.0M$15.0M$24.0M$26.0M$7.0M
Operating Profit$-111.0M$-63.0M$-72.0M$-67.0M$-114.0M
Net Profit$-110.0M$-61.0M$-66.0M$-64.0M$-21.0M
EPS$-12.41$-2.69$-2.44$-2.36$-0.33
Op Margin-9930.1%-411.9%-295.4%-259.6%-1601.1%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$158.0M$184.0M$132.0M$70.0M$151.0M
Total Liabilities$22.0M$26.0M$27.0M$18.0M$15.0M
Cash$149.0M$39.0M$63.0M$29.0M$38.0M
Borrowings$1.0M$2.0M$1.0M$1.0M$0

Latest News

Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity GlobeNewswire · Jul 22, 2026 Akari Therapeutics, Whitehawk Therapeutics Collaborate to Develop ADC Cancer Treatments MT Newswires · Jul 21, 2026 Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics GlobeNewswire · Jul 21, 2026 Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development Business Wire · Jul 7, 2026 B. Riley Initiates Whitehawk Therapeutics at Buy With $10 Price Target MT Newswires · Jun 25, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-22.0M$-50.0M$-60.0M$-60.0M$-97.0M
Investing Cash Flow$25.0M$-133.0M$79.0M$24.0M$11.0M
Financing Cash Flow$-9.0M$0$0$0$-6.0M
Net Cash Flow$145.0M$-110.0M$24.0M$-34.0M$9.0M
Free Cash Flow$-22.0M$-50.0M$-64.0M$-61.0M$-98.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-46.95%
Quick Ratio11.36
Interest Coverage—
Return 1Y85.85%
Return 3Y-33.62%
Return 5Y-87.36%

Ownership

Insiders Held13.38%
Institutions Held73.24%
Institutions Float Held84.56%
Institutional HolderSharesReport Date
QVT Financial LP4,615,7092026-03-31
Orbimed Advisors LLC.4,166,0002026-03-31
Suvretta Capital Management, LLC3,700,0002026-03-31
Acuta Capital Partners LLC3,410,4022026-03-31
Avoro Capital Advisors LLC2,849,4022026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ATOS $2.36 -2.48% -1.23 $23.54M 0.00%
CLNNClene Inc. $5.29 -1.86% -1.66 $54.53M 0.00%
CNTX $0.62 +4.47% -6.84 $56.69M 0.00%
IMMX $8.55 +4.65% -9.96 $465.14M 0.00%
MGNX $3.78 +3.00% -2.92 $240.27M 0.00%

About WHWK

WHWK is led by CEO David J. Lennon, employs 40 people, headquartered in US, publicly traded since 2017.

WHWK stock trades at $4.07 with a market capitalization of $201.27M. The stock is valued at a price-to-earnings (P/E) ratio of -12.79, price-to-book of 1.53, price-to-sales of 29.81. Over the past 52 weeks the stock has ranged between $1.57 and $5.50, and currently trades 25.9% below its 52-week high.

On profitability, WHWK generates a return on equity (ROE) of -15.44%, return on capital employed of -83.82%, an operating margin of -1628.57%, a net profit margin of -300.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides